At Polpharma Biologics, our commitment to excellence begins at the top. With decades of combined experience in the development, manufacture and commercialization of biopharmaceuticals, our international management team brings both knowledge and passion to every project.
Jerzy Starak, Chairman of the Supervisory Board of Polpharma Biologics S.A, belongs to the group of Polish entrepreneurs, whose activities contributed to the modernization of the Polish economy. Visionary, who does not lack the courage, determination and perseverance in making difficult business challenges. Thanks to his activity, companies such as Baxter, Bols, Lessafre, Sanofi, Bunge, Nutricia and Colgate-Palmolive, appeared in Poland. In 2000, became the owner of Polpharma S.A. in Starogard Gdanski, joined by Medana Pharma S.A. Sieradz Branch Duchnice purchased from the company Bioton Warsaw Polfa S.A. and the company Sanfarm, transformed into a branch of Production in Nowa Deba.
Hannes Teissl is a seasoned biopharmaceutical executive with a track record in general management, business turnaround, finance, business development and M&A. Hannes is a Supervisory Board Member of Polpharma Biologics S.A., a company which he was instrumental in establishing over the last 7 years. Prior to joining Polpharma Biologics, Hannes served 22 years at Sandoz, where he held various international management positions, such as Member of the Global Executive Committee, Global Head of M&A, CEO of Sandoz Germany, Global Head of Biopharmaceuticals, Global Commercial Head of API & Out-Licensing for an Anti-infectives and CEO of Sandoz Germany. Hannes holds a Master of Economics from the University of Innsbruck.
Dr. Joerg Windisch
President of the Management Board
Dr. Joerg Windisch has around 25 years of experience in the development, manufacture and regulatory licensure of biologic therapies. Since joining Polpharma Biologics, Dr. Windisch has made significant contributions to the organization’s formation and growth, and the development of its frontrunner products. Prior to joining Polpharma, Dr. Windisch served as the Chief Operating Officer (COO) for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer. Before that, Dr. Windisch spent almost 20 years at Novartis/Sandoz where he most recently served as Chief Scientific Officer (CSO) for Sandoz Biopharmaceuticals. He was a key figure in developing the first biosimilars approved in Europe and the US.
Member of the Management Board
Jan Krzewinski is a Management Board Member and CFO of Polpharma Biologics. Prior to his current position Jan held various roles at Polpharma including the Director of the Chariman’s Strategic Projects Office. Before joining Polpharma he spent almost 9 years working for Mid Europa Partners, the largest CEE-focused private equity fund where he was responsible for executing and monitoring investments. While at Mid Europa Partners Jan held supervisory board-level positions at Lux Med, Diagnostyka, Alpha Medical and Polskie Koleje Linowe. Jan continues to serve on the supervisory boards of Herbapol Lublin and the EFC Educational Foundation. Jan is a graduate of the London School of Economics and Political Science (BSc) and Johns Hopkins University, SAIS (MA).
Dr. Nicholas Hunt
Director Technical Research
Dr. Nicholas Hunt has more than 25 years of experience in the Biotech/Pharma sector and after having received his BSc in Microbiology and Virology and a PhD in Molecular Virology both from the University of Warwick, UK he has worked in and managed a number of different R&D organizations in a variety of companies in a number of countries. His experience includes leading large multi interdisciplinary R&D groups in developing novel and Biosimilar medicines as well as multi-site CMO GMP manufacturing companies such as Richter-Helm-Biologics. He has spent the last six years at Alvotech in Iceland where from the very beginning of this venture he was instrumental in building up the CMC target portfolio and GMP manufacturing competencies as well as state of the art single use mammalian manufacturing facility. During this period he also taught Biotechnology at the University of Iceland.
Dr. Adriana Kiędzierska-Mencfeld
Technical Operations Director
Dr. Kiędzierska-Mencfeld has more than 10 years of experience in recombinant protein purification and expression in both prokaryotic and eukaryotic systems, and six years of experience in the development and GMP production of biosimilars. Prior to joining Polpharma Biologics as Production Director, Dr. Kiedzierska-Mencfeld spent four years as Head of GMP Production at the biotechnology firm Mabion S.A. She earned her Ph.D. in biochemistry from the Institute of Biochemistry and Molecular Biology at the University of Wroclaw, her MS in molecular biotechnology and biocatalysis from the Technical University of Wroclaw, and completed her master’s thesis at the Technical University of Dresden.
Marlena Nowak has more than 23 years of experience in the pharmaceutical industry. She started at Polpharma as a QC Specialist, and she continued in the same role for a further next 4 years as a QA Specialist. Then she moved to GSK to work in the QA operationsal area. In 2005, again Marlena came back to work for Polpharma in Starogard Gdański, to lead the QA operations team. Prior to joining Polpharma Biologics as Quality Director, Marlena spent 4 years as Quality Assurance Manager and 5 years as Site Quality Head, leading 2 sites in Poland, at Novartis. She has an MSc in chemistry from Gdańsk University. Marlena is a board member of the Polish ISPE Polish Affiliate.
Dr. Piotr Zień
Director Science & Innovation
Dr. Piotr Zień is an experienced R&D professional skilled in biopharmaceutical drugs development. As a Research and Development Director for Polpharma Biologics, Piotr manages the organization’s biopharmaceutical laboratory in Gdańsk, with responsibility for the in-house development of biosimilar molecules. Piotr has more than 15 years of experience in the biotech sector, during which he was the leader of the development projects both for innovative and biosimilar molecules. Piotr graduated from UMCS in Lublin with an MSc in the faculty of biotechnology and with a Ph.D. in molecular biology from the Catholic University of Lublin. He participated in a postdoctoral fellowship in the department of biochemistry at the University of Western Ontario and is a member of the program board in the leading Polish university in Gdańsk.
Lidia Ołowska is HR professional with more than 20 years of international experience in pharmaceutical sector, global organizations and matrix setups. Prior to joining Polpharma Biologics Lidia has served as HR & Communication Director for Novo Nordisk A/S in Poland, Russia and Italy being responsible for setting and execution of HR strategy in more than 25 countries of Europe and Asia as well as start-up of the first greenfield, modern insulin production facility in Russia. She is focused on contributing to the business by ensuring organization excellence, enhancing leadership and developing solutions for the business objectives delivery. Lidia is a graduate of Oxford Brookes University (MBA), has completed post-graduate studies in Coaching at SWPS University of Social Sciences and Humanities and HR Strategies at Warsaw School of Economics.
Tomasz Góralczyk has more than 17 years of experience in pharmaceutical business development, including both licensing-in and licensing-out. Tomasz started at Polpharma as New Product Acquisition Manager, identifying and initiating opportunities to expand the organization’s portfolio of products. He then led the formation of Polpharma’s out-licensing department and strategy as Licensing-Out Director, where he was responsible for licensing out products developed by the Polpharma group of companies. Prior to his time at Polpharma, Tomasz was Head of the Foreign Projects Department at Adamed. He has an MSc in molecular biology from Jagiellonian University in Kraków.
Head Operational Finance
Andrzej Uzdrowski has more than 13 years of professional experience in finance and is currently responsible for operational and strategic controlling at Polpharma Biologics. Prior to joining Polpharma Biologics, he worked in the generics division of Polpharma Group as Head of R&D and B2B Controlling for 11 years, during which time he successfully implemented a number of solutions that increased the quality of the organization’s financial reporting. Andrzej received his master’s degree in international finance and banking from Gdańsk University and completed his post-graduate studies in accounting and controlling at BSB University.
Dr. Louis Boon
Chief Scientific Officer, Bioceros
Dr. Louis Boon is Chief Scientific Officer and Managing Director for Bioceros, a division of Polpharma Group. He is experienced in molecular and cellular immunology and therapeutic antibody development, and has been involved in the trajectory of preclinical preparation and design of first-into-man studies using therapeutic antibodies. A founder of Bioceros BV, Dr. Boon has held various scientific management roles throughout his career, including CSO for 4AZA Bioscience NV and Director of Preclinical R&D for MacroZyme BV. After completing his post-doctoral studies, Dr. Boon helped to found PanGenetics, where he would later hold the position of VP Preclinical (ad interim) following the company’s merger with Tanox Inc. He received his Ph.D. in biochemistry from the University of Amsterdam and completed his post-doctoral work at the University of Amsterdam’s Department of Anatomy and Embryology and Department of Clinical Epidemiology.
Dr. Abraham Bout
Dr. Bram Bout is Chief Executive Officer and Managing Director of Bioceros, a division of Polpharma Group. Earlier, he was Chief Technology Officer at Profibrix BV. Prior to joining Bioceros, Dr. Bout held several management positions with increasing responsibility at Crucell, including Vice President, Protein Production. Dr. Bout is co-inventor of the human PER.C6 production platform, which is used for the development and manufacture of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy products. He studied chemistry at the University of Amsterdam and wrote his Ph.D. thesis on peroxisomal storage disorders. Dr. Bout has published over 50 scientific articles and is co-inventor on 90 patents for the PER.C6 cell line technology and the field of recombinant protein production and gene therapy.
Mission and Vision
We aim to develop high-quality biologic medicines to treat a wide range of conditions and to make these therapies accessible to those who need them.
Employee Attitudes & Behaviors
We adhere to a set of guiding principles meant to foster a positive, enriching atmosphere for our staff and deliver value to all of our stakeholders.